QIAGEN N.V. [QGEN] Filings |
|
20-F | [2024-03-11] |
20-F | [2023-03-13] |
20-F | [2022-03-14] |
20-F | [2021-03-05] |
20-F | [2020-03-02] |
20-F | [2019-03-06] |
20-F | [2018-03-06] |
20-F | [2017-03-06] |
20-F | [2016-02-29] |
20-F | [2015-03-02] |
20-F | [2014-03-03] |
20-F | [2013-03-04] |
20-F | [2012-03-27] |
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report |
Title of class: | Trading Symbol | Name of each exchange on which registered: | ||
☒ | |
☐ | International Financial Reporting Standards as issued by the International Accounting Standards Board |
☐ | Other |
Table of Contents | |
QIAGEN N.V. | Financial Report 2023 | Page 6 | ||||||||||||||||||||
Overview |
2023 | ||
Year-end market capitalization (in $ million) | 9,911 | |
Year-end market capitalization (in € million) | 8,991 |
QIAGEN N.V. | Financial Report 2023 | Page 7 | ||||||||||||||||||||
Overview |
2023 | ||
Year-end price | $43.43 | |
High | $51.18 | |
Low | $34.74 | |
Average daily trading volume (in million shares) | 1.02 |
QIAGEN N.V. | Financial Report 2023 | Page 8 | ||||||||||||||||||||
Overview |
QIAGEN N.V. | Financial Report 2023 | Page 9 | ||||||||||||||||||||
Overview |
High ($) | Low ($) | |||
Annual: | ||||
2019 | 43.16 | 25.04 | ||
2020 | 55.27 | 32.97 | ||
2021 | 59.00 | 45.58 | ||
2022 | 55.12 | 40.38 | ||
2023 | 51.18 | 34.74 |
High ($) | Low ($) | |||
Quarterly 2022: | ||||
First Quarter | 55.12 | 41.32 | ||
Second Quarter | 50.38 | 42.44 | ||
Third Quarter | 50.51 | 40.49 | ||
Fourth Quarter | 51.05 | 40.38 | ||
Quarterly 2023: | ||||
First Quarter | 51.18 | 45.08 | ||
Second Quarter | 46.99 | 43.80 | ||
Third Quarter | 47.70 | 38.98 | ||
Fourth Quarter | 43.73 | 34.74 | ||
Quarterly 2024: | ||||
First Quarter (through March 7) | 45.87 | 42.17 |
High ($) | Low ($) | |||
Monthly: | ||||
October 2023 | 40.65 | 34.74 | ||
November 2023 | 41.48 | 37.14 | ||
December 2023 | 43.73 | 40.78 | ||
January 2024 | 45.87 | 42.73 | ||
February 2024 | 45.38 | 42.17 | ||
March 2024 (through March 7) | 44.65 | 42.60 |
2023 | ||
Year-end price | €39.40 | |
High | €48.36 | |
Low | €32.74 | |
Average daily trading volume (in million shares) | 0.51 |
QIAGEN N.V. | Financial Report 2023 | Page 10 | ||||||||||||||||||||
Overview |
QIAGEN N.V. | Financial Report 2023 | Page 11 | ||||||||||||||||||||
Overview |
High (€) | Low (€) | |||
Annual: | ||||
2019 | 39.19 | 22.54 | ||
2020 | 46.95 | 29.55 | ||
2021 | 51.56 | 37.38 | ||
2022 | 49.37 | 37.95 | ||
2023 | 48.36 | 32.74 |
High (€) | Low (€) | |||
Quarterly 2022: | ||||
First Quarter | 49.34 | 37.95 | ||
Second Quarter | 46.03 | 39.94 | ||
Third Quarter | 49.37 | 41.32 | ||
Fourth Quarter | 48.26 | 41.62 | ||
Quarterly 2023: | ||||
First Quarter | 48.36 | 41.57 | ||
Second Quarter | 43.47 | 39.62 | ||
Third Quarter | 43.39 | 36.73 | ||
Fourth Quarter | 40.07 | 32.74 | ||
Quarterly 2024: | ||||
First Quarter (through March 7) | 42.19 | 38.83 |
High (€) | Low (€) | |||
Monthly: | ||||
October 2023 | 38.64 | 32.74 | ||
November 2023 | 37.83 | 35.09 | ||
December 2023 | 40.07 | 37.46 | ||
January 2024 | 42.10 | 38.83 | ||
February 2024 | 42.19 | 39.07 | ||
March 2024 (through March 7) | 41.05 | 39.32 |
QIAGEN N.V. | Financial Report 2023 | Page 12 | ||||||||||||||||||||
Overview |
QIAGEN N.V. | Financial Report 2023 | Page 13 | ||||||||||||||||||||
Management Report |
QIAGEN N.V. | Financial Report 2023 | Page 14 | ||||||||||||||||||||
Management Report |
QIAGEN N.V. | Financial Report 2023 | Page 15 | ||||||||||||||||||||
Management Report |
Applications | |||||
Cloning | qPCR / dPCR | ||||
DNA amplification | Sequencing / NGS | ||||
Arrays | Liquid biopsy | ||||
Gene editing | Microbiome | ||||
Epigenetics | Gene silencing | ||||
Cellular analytics | Proteomics | ||||
Input demands | Processing | Target analytes |
Low / high-volume | Manual | Genomic DNA |
Low-quantity | Plasmid DNA | |
Tubes / plates | cfDNA | |
Input demands | ||
Low-quantity | Automated | mRNA, rRNA |
High-quantity | Low-to | miRNA |
Tubes / plates | High-throughput | Proteins Circ. Tumor cells |
Selected biological samples | |||||
Tissue | Stool | ||||
Cells | Saliva | ||||
Blood | Other body fluids | ||||
Serum | Bone | ||||
Plasma | Plants | ||||
Urine | Soil |
Sample technologies | Selected QIAGEN brands | |||
Primary Sample technology consumables | ||||
•Nucleic acid stabilization and purification kits designed for primary sample materials (DNA, RNA), manual and automated processing for genotyping, gene expression, viral and bacterial analysis •Mainly based on silica membrane and magnetic bead technologies | •QIAamp •PAXgene •AllPrep | •DNeasy •AdnaTest •QIAprep& | •RNeasy •MagAttract | |
Secondary Sample technology consumables | ||||
•Kits and components for purification of nucleic acids from secondary sample materials (e.g., gel, plasmid DNA) | •QIAprep •QIAGEN Plasmid •HiSpeed | •QIAquick •QIAfilter •EndoFree | •DyeEx | |
Sample technology instruments | ||||
•Instruments for nucleic acid purification, quality control and accessories | •QIAsymphony •EZ1 Advanced XL •TissueLyser III | •QIAcube Connect •EZ2 Connect MDx •QIAxpert | •QIAcube HT •QIAxcel Connect •QIAcube Connect MDx |
Diagnostic solutions | Selected QIAGEN brands | |||
Immune response consumables | ||||
•Interferon-Gamma Release Assay (IGRA) for latent TB testing •Assays for post-transplant testing, viral load monitoring, assessment of T-Cell response to COVID-19 | •QuantiFERON | |||
Oncology and Sexual & Reproductive health consumables | ||||
•Assays for analysis of genomic variants such as mutations, insertions, deletions and fusions •Assays for prenatal testing and detection of sexually transmitted diseases and HPV | •therascreen •AmniSure / PartoSure | •ipsogen | •digene HC2 | |
Sample to Insight instruments and dedicated assays | ||||
•One-step molecular analysis of hard-to-diagnose syndromes •Fully integrated PCR testing | •QIAstat-Dx •QIAstat-Dx Rise | •NeuMoDx |
QIAGEN N.V. | Financial Report 2023 | Page 16 | ||||||||||||||||||||
Management Report |
PCR/Nucleic acid amplification | Selected QIAGEN brands | |||
Research PCR consumables | ||||
•Different generations of PCR, quantitative PCR, reverse transcription and combinations (RT-PCR) kits for analysis of gene expression, genotyping and gene regulation, running on QIAGEN or third-party instruments and technologies | •QuantiTect •OneStep RT-PCR •Type-it •OmniScript | •QuantiFast •QIAGEN Multiplex •miRCURY LNA •miScript | •QuantiNova •HotStarTaq •TopTaq | |
Human ID / Forensics assay consumables | ||||
•STR assays for Human ID, additional assays for food contamination | •Investigator (human ID / forensics) | •mericon (food safety) | ||
PCR instruments | ||||
•Digital PCR solutions •qPCR solutions | •QIAcuity •Rotor-Gene Q | •QIAquant •QIAgility | ||
OEM consumables | ||||
•Custom-developed and configured enzymes and PCR solutions that are sold to OEM customers | •Provided on an individualized contract basis |
QIAGEN N.V. | Financial Report 2023 | Page 17 | ||||||||||||||||||||
Management Report |
Genomics / NGS | Selected QIAGEN brands | |||
Universal NGS consumables | ||||
•Predefined and custom NGS gene panels (DNA, RNA), library prep kits and components, whole genome amplification, etc. •Sequence-based assays for forensic genetic genealogy | •QIAseq | •REPLI-g Epitect | •ForenSeq Kintelligence | |
QIAGEN Digital Insights solutions | ||||
•Bioinformatics solutions analyze and interpret data to deliver actionable insights from NGS. This includes freestanding software or cloud-based solutions and is also integrated into many QIAGEN consumables and instruments | •QIAGEN Clinical Insight •QCI Interpret One •Ingenuity Variant Analysis | •CLC Genomics Workbench •OmicSoft •Ingenuity Pathway Analysis | • |